Which GLP-1 works best? New meta-study puts them head-to-head
A new meta-analysis from the University of Georgia compared the effectiveness of tirzepatide, semaglutide, and liraglutide for weight loss. The data indicates tirzepatide may be the most effective option for non-diabetic patients. Tirzepatide is marketed under the brand names Zepbound and Mounjaro.
What changed
A University of Georgia meta-analysis and head-to-head trials have identified tirzepatide as more effective for weight loss than semaglutide.
Live updates
-
University of Georgia Meta-Analysis Compares GLP-1 Weight Loss Efficacy
confidence 95%A new meta-analysis from the University of Georgia compared the effectiveness of tirzepatide, semaglutide, and liraglutide for weight loss. The data indicates tirzepatide may be the most effective option for non-diabetic patients. Tirzepatide is marketed under the brand names Zepbound and Mounjaro.
What's confirmed:
- A University of Georgia meta-analysis compared tirzepatide, semaglutide, and liraglutide.
- Tirzepatide is sold under the brand names Zepbound and Mounjaro.
- Semaglutide is sold as Wegovy and Ozempic.
- Liraglutide is known as Saxenda and Victoza.
- Tirzepatide outperforms semaglutide for real-world weight loss.
- Zepbound beat Wegovy in the first head-to-head trial comparing the two obesity drugs.
- For non-diabetic patients, tirzepatide may be the most effective GLP-1 medication.
Still unconfirmed:
- Setting a goal weight may lead to greater success with GLP-1s like Zepbound.